---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-061148"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-05-14T20:06:05+00:00"
generated_at: "2026-05-14T21:01:20.962367+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726

## Summary
- Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.
- Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.
- First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.
- January 2026 public offering raised ~$9.3M gross proceeds to fund operations.
- R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M.

## SEC filing metadata
- accession: 0001104659-26-061148
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-05-14T20:06:05+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/0001104659-26-061148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-061148
- JSON: https://secwatch.observer/filing/0001104659-26-061148.json
- Plain text: https://secwatch.observer/filing/0001104659-26-061148.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: issued a press release announcing its financial results for the first quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/0001104659-26-061148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.